AMAG Pharmaceuticals (AMAG) Earns Hold Rating from B. Riley
B. Riley restated their hold rating on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a research note released on Tuesday. The brokerage currently has a $16.00 target price on the specialty pharmaceutical company’s stock. B. Riley also issued estimates for AMAG Pharmaceuticals’ FY2022 earnings at $1.78 EPS.
A number of other research analysts have also recently issued reports on the stock. ValuEngine raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, January 3rd. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, November 8th. Jefferies Group reaffirmed a buy rating and issued a $16.00 target price on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Morgan Stanley dropped their target price on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a report on Friday, November 3rd. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $21.27.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.30 during midday trading on Tuesday, reaching $13.95. 959,742 shares of the company traded hands, compared to its average volume of 827,891. The stock has a market capitalization of $492.27, a PE ratio of -2.29 and a beta of 0.79. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.
Hedge funds have recently added to or reduced their stakes in the company. Hartford Investment Management Co. acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $186,000. Cubist Systematic Strategies LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. 361 Capital LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Aperio Group LLC acquired a new stake in shares of AMAG Pharmaceuticals in the third quarter valued at approximately $198,000. Finally, Municipal Employees Retirement System of Michigan grew its position in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 4,870 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.